Category: Research Peptides | Reading time: 5 min | For research use only
TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells. It corresponds to the active region of Thymosin Beta-4 responsible for actin binding — specifically the amino acid sequence LKKTETQ. Since its identification, TB-500 has been the subject of preclinical research examining its role in cytoskeletal organization, cell migration, and tissue modeling processes.
This article summarizes published research on TB-500 for scientific and educational purposes. All compounds discussed are strictly for laboratory and research use only.
Molecular Profile
- Full name: Thymosin Beta-4 fragment (Tβ4 17–23)
- Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
- Molecular weight: 887.0 g/mol
- Form: Lyophilized powder (research grade)
- Stability: Store at −20°C; avoid repeated freeze-thaw cycles
- Solubility: Soluble in sterile water or bacteriostatic water
TB-500's relatively small molecular weight compared to full-length Thymosin Beta-4 makes it a practical research tool for studying the actin-binding domain specifically, isolated from the broader Tβ4 molecule.
Mechanisms Studied in Preclinical Research
Actin sequestration and cytoskeletal dynamics Thymosin Beta-4 — and by extension TB-500 — is one of the most abundant actin-sequestering proteins in mammalian cells. Research has examined its role in regulating the balance between monomeric (G-actin) and filamentous (F-actin) pools, a process fundamental to cell shape, motility, and division. Studies using TB-500 have investigated how actin dynamics modulation affects cellular behavior in tissue modeling contexts.
Cell migration research Multiple in vitro studies have examined TB-500's effect on cell migration rates in scratch assay and transwell models. Publications have reported increased migration velocity in endothelial cell and keratinocyte cultures treated with TB-500, with researchers attributing this to actin polymerization dynamics at the leading edge of migrating cells.
Angiogenesis models TB-500 has been studied in models examining new blood vessel formation. In vitro tube formation assays and in vivo Matrigel plug assays have been used to investigate whether TB-500 influences endothelial cell organization into capillary-like structures, with several publications reporting positive associations.
Anti-inflammatory signaling Research in rodent models has examined TB-500 in the context of inflammatory markers. Studies have investigated its interaction with NF-κB signaling pathways and its association with downregulation of pro-inflammatory cytokines including IL-1β and TNF-α in treated animal models.
Cardiac tissue research A notable body of research has examined Thymosin Beta-4 and TB-500 in cardiac models. Studies published in cardiovascular journals have investigated cardiomyocyte survival, epicardial cell activation, and progenitor cell mobilization in ischemic heart models, making this one of the more extensively published research areas for this compound class.
Areas of Active Research
Connective tissue models Tendon, ligament, and muscle tissue research has used TB-500 in animal models examining organizational changes in extracellular matrix components following mechanical injury. Histological analysis in these studies has documented collagen fiber organization patterns in treated versus control groups.
Ocular surface research Thymosin Beta-4 has FDA orphan drug designation for dry eye syndrome, reflecting clinical research interest in corneal applications. TB-500 fragment research has paralleled this interest, with in vitro corneal epithelial cell migration models representing an active research area.
Neural tissue models More recent literature has examined Thymosin Beta-4 derivatives in neural contexts, including oligodendrocyte precursor cell research and models examining remyelination processes. This represents an emerging rather than established area of TB-500 specific research.
Key Published Research
- Goldstein AL, Hannappel E, Kleinman HK. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429.
- Smart N, et al. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.Nature, 445, 177–182.
- Sosne G, et al. (2010). Thymosin beta 4 and cornea: the promise of a new therapy. Annals of the New York Academy of Sciences, 1194, 190–198.
- Philp D, et al. (2004). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal and epidermal regeneration in mice with full-thickness wounds. Wound Repair and Regeneration, 12(4), 397–405.
Research Considerations
TB-500 is a fragment peptide, and researchers should be attentive to the distinction between full-length Thymosin Beta-4 literature and studies specifically using the TB-500 fragment. While the actin-binding domain is conserved, full-length Tβ4 has additional biological activities not attributable to TB-500 alone.
As with all research peptides, purity is a critical experimental variable. Researchers should obtain batch-specific COA documentation confirming HPLC purity prior to use, as impurities can confound experimental outcomes particularly in cell-based assays.
NordBioLab supplies TB-500 as a research-grade lyophilized peptide with ≥98% purity (HPLC verified) and full COA documentation per batch.
All products and information provided by NordBioLab are strictly for scientific research and laboratory use only. Not for human or veterinary consumption. This article does not constitute medical advice.